NantHealth (NH) Upgraded by BidaskClub to Sell

BidaskClub upgraded shares of NantHealth (NASDAQ:NH) from a strong sell rating to a sell rating in a research note published on Tuesday.

Several other analysts also recently issued reports on NH. Zacks Investment Research downgraded shares of NantHealth from a buy rating to a hold rating in a report on Tuesday. Jefferies Group reiterated a buy rating and set a $5.00 target price on shares of NantHealth in a research note on Thursday, September 28th. Finally, Canaccord Genuity cut their target price on shares of NantHealth from $6.00 to $5.00 and set a buy rating for the company in a research note on Friday, November 17th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. NantHealth has a consensus rating of Buy and an average price target of $8.05.

NantHealth (NASDAQ NH) traded up $0.01 during midday trading on Tuesday, hitting $3.77. 194,612 shares of the company traded hands, compared to its average volume of 157,598. The company has a current ratio of 2.38, a quick ratio of 2.36 and a debt-to-equity ratio of 0.93. The company has a market cap of $407.32, a P/E ratio of -2.12 and a beta of -1.50. NantHealth has a fifty-two week low of $2.60 and a fifty-two week high of $10.19.

NantHealth (NASDAQ:NH) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. The business had revenue of $21.76 million during the quarter, compared to the consensus estimate of $29.42 million. NantHealth had a negative net margin of 225.76% and a negative return on equity of 46.09%. NantHealth’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.18) EPS. sell-side analysts anticipate that NantHealth will post -1.35 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in NH. Dimensional Fund Advisors LP acquired a new position in NantHealth during the 3rd quarter valued at $365,000. Northern Trust Corp raised its stake in NantHealth by 133.9% during the 2nd quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock valued at $643,000 after purchasing an additional 86,955 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in NantHealth by 91.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock valued at $717,000 after purchasing an additional 81,024 shares during the last quarter. Vanguard Group Inc. raised its stake in NantHealth by 20.2% during the 2nd quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock valued at $1,792,000 after purchasing an additional 71,087 shares during the last quarter. Finally, State Street Corp raised its stake in NantHealth by 88.1% during the 2nd quarter. State Street Corp now owns 147,234 shares of the company’s stock valued at $623,000 after purchasing an additional 68,963 shares during the last quarter. Hedge funds and other institutional investors own 7.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.themarketsdaily.com/2018/01/14/nanthealth-nh-upgraded-by-bidaskclub-to-sell.html.

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply